AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study
Status:
Terminated
Trial end date:
2019-10-07
Target enrollment:
Participant gender:
Summary
The APPLE pilot trial is a feasibility study that is a multicentre, open-label, randomized
controlled trial. Pregnant women with antiphospholipid syndrome (APS) and a history of late
(≥10 weeks gestation) or recurrent early (2 <10 weeks) pregnancy loss will be recruited.
Eligible and consenting subjects will be assigned to one of two study arms: open-label
low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin
(ASA) daily until delivery, or open-label low-dose aspirin daily from randomization until
delivery.